KVA 12123
Alternative Names: KVA-001; KVA-002; KVA-12.1; KVA-12123Latest Information Update: 11 Jul 2024
At a glance
- Originator GigaGen
- Developer Kineta
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Acute myeloid leukaemia; Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 08 Jul 2024 TuHURA Biosciences enters into an agreement to acquire KVA 12123 from Kineta
- 08 Jul 2024 Kineta plans to initiate a phase II trial for Solid tumours (Late-stage disease) in third quarter of 2024 (Kineta pipeline, June 2024)
- 08 May 2024 Kineta has patent protection for KV001 in USA, Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Korea, Mexico, Russia, and Singapore